What did Cantor Fitzgerald say in its March 10, 2026 note?

Cantor Fitzgerald reiterated an **Overweight** on LFMD on March 10, 2026, citing momentum across the offering and strong Q4 results. The note did not include a new LFMD price target.

How should investors interpret the LFMD analyst rating?

The LFMD analyst rating of Overweight signals expected outperformance versus peers per Cantor Fitzgerald. Investors should use it alongside valuation, guidance, and Meyka AI’s B+ grade before making decisions.

Did the analyst note include a price target for LFMD?

No. The March 10, 2026 Cantor Fitzgerald reiteration did not publish a new LFMD price target. Investors should look to future notes or company guidance for targets.

How did the market respond to the LFMD analyst rating?

Shares rose **+3.3% ($0.12)** after the reiteration, showing positive short-term reaction to the LFMD analyst rating and the supporting Q4 results coverage.

Analyst Ratings

Cantor Fitzgerald Maintains Overweight on LifeMD, Inc. (LFMD) March 2026

ByDanny Kontos March 11, 2026March 11, 2026

Cantor Fitzgerald reiterated an Overweight on LifeMD, Inc. (LFMD) on March 10, 2026, the headline LFMD analyst rating update. The firm cited momentum across the company offering after a solid Q4 print, which helped send the shares higher. Street reports show a +3.3% ($0.12) move after the note. There was no new price target in the published note. Meyka AI rates LFMD with a grade of B+, reflecting benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.